Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2024-05-07 Capital/Financing Update
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Przyjęcie planu budowy wielkoskalowej wytwórni komórek macierzystych i sposobu jej finansowania - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text explicitly discusses the intent to finance the construction of a new stem cell manufacturing plant through a non-prospectus public offering of shares ('Oferta'). It details the structure of this offering, including the maximum percentage of shares to be offered (up to 20%), the exclusion of pre-emptive rights, and the planned timing (June 2024). The text also mentions that the decision for this capital increase requires a resolution from the General Meeting. Since the core subject is a planned capital increase/share issuance ('emisji nowych akcji') intended to fund expansion, this aligns directly with the 'Capital/Financing Update' definition. Although it mentions a potential share offering, the primary focus is the financing plan itself, making 'CAP' more appropriate than 'SHA' (which is usually for the announcement of the completed issue or change) or 'PSI' (which relates to proxy solicitation for a meeting, although a resolution is needed). Given the detailed financing and capital structure discussion, CAP is the best fit.
2024-05-07 Polish
Podpisy do opinii biegłego rewidenta z badania Sprawozdania Finansowego Bioceltix S.A. za okres 01.01.2023-31.12.2023 r.
Audit Report / Information Classification · 1% confidence The document text consists almost entirely of XML signature blocks (Signature, SignedInfo, SignatureValue, KeyInfo, etc.). Within the structure, there are references to a file named "BIOCELTIX_BSF_2023_Sprawozdanie_z_badania_JZP_PSR.xhtml". The Polish phrase "Sprawozdanie z badania" translates to "Audit Report" or "Examination Report". Furthermore, the presence of a digital signature and certificate information strongly suggests this is a formal, legally required document that has been authenticated. Given the content points directly to an audit report, the appropriate classification is 'Audit Report / Information' (AR). The document length (10,059 chars) is substantial enough to contain the report content, not just a brief announcement, thus bypassing the RPA/RNS rule for short announcements. FY 2023
2024-04-26 Polish
Opinia biegłego rewidenta z badania Sprawozdania Finansowego Bioceltix S.A. za okres 01.01.2023-31.12.2023 r.
Audit Report / Information Classification · 1% confidence The document text is titled 'Raport Sprawozdanie niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego...' which translates to 'Report of the independent certified auditor on the audit of the annual financial statements...'. It explicitly details the scope of the audit, the opinion given on the financial statements (balance sheet, income statement, cash flow statement) for the year ended December 31, 2023, and references Polish accounting laws ('ustawa o rachunkowości') and auditing standards (KSB/ISA). This content perfectly matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, distinct from the full Annual Report (10-K) or an announcement of a report (RPA). FY 2023
2024-04-26 Polish
Podpisy do Raportu okresowego rocznego Bioceltix S.A. za rok 2023
Regulatory Filings Classification · 1% confidence The document text consists entirely of XML digital signature blocks (XAdES format) referencing an external file named 'RaportRoczny2023ZZ_2023-12-31_pl.xhtml'. It does not contain the actual financial statements or content of the report itself, but rather serves as the cryptographic validation/certification of the report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS). FY 2023
2024-04-26 Polish
Raport okresowy roczny Bioceltix S.A. za rok 2023
Annual Report Classification · 1% confidence The document is explicitly titled 'Raport Roczny 2023' (Annual Report 2023) for the company Bioceltix S.A. It contains a comprehensive structure including a letter from the management, a table of contents, selected financial data, the full annual financial statements, and the management report on activities. It is a full-length annual report covering the fiscal year 2023, not an announcement or a summary. FY 2023
2024-04-26 Polish
Podpisy do Sprawozdania z Działalności Bioceltix S.A. za okres sprawozdawczy zakończony 31.12.2023 r.
Audit Report / Information Classification · 1% confidence The provided document text consists entirely of XML digital signature blocks (specifically XAdES signatures) referencing a file named "SprawozdZarz_BCX_2023-12-31_pl.xhtml". The presence of Polish text ("SprawozdZarz" likely meaning 'Management Report' or similar) and the structure strongly suggest this is metadata or a wrapper containing signatures for a financial document, rather than the document content itself. Since the content is not the actual report but rather the signature/verification data, and given the reference to a 'Sprawozdanie Zarządu' (Management Report) for the period ending 2023-12-31, this document is most likely an announcement or wrapper related to the filing of that report. However, the text provided is purely the signature block, which often accompanies filings like the 10-K or IR, but is not the report itself. Since the document length is substantial (20872 chars) and it contains detailed signature information rather than a brief announcement stating a report is attached, it is less likely to be a simple RPA/RNS. The referenced file name 'SprawozdZarz' points towards a Management Report. In the provided schema, 'Management Reports' (MDA) is the closest fit for a Management Report, even though we are only seeing the signature block for it. If this were a wrapper announcing the filing, RPA would be appropriate, but the sheer volume of signature data suggests it might be an embedded part of a larger filing or the signature block itself is being submitted as a standalone item related to the report. Given the context of Polish financial reporting, 'Sprawozdanie Zarządu' maps best to Management's Discussion and Analysis (MDA). I will classify it as MDA based on the content reference, assuming the signature block is part of the submission for that specific report type. FY 2023
2024-04-26 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.